Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety

Leukemia

Volumn 24, Issue 6, 2010, Pages 1160-1170

  Hoyos, V ^a   Savoldo, B ^a   Quintarelli, C ^a   Mahendravada, A ^a   Zhang, M ^a   Vera, J ^a   Heslop, H E ^a,b   Rooney, C M ^a,b,c   Brenner, M K ^a,b   Dotti, G ^a,c  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

chimeric antigen receptor; IL 15; suicide gene

Indexed keywords

ANTILEUKEMIC AGENT; CASPASE 9; CD19 ANTIGEN; LYMPHOCYTE ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; RECOMBINANT INTERLEUKIN 15; CD28 ANTIGEN; INTERLEUKIN 15;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CONTROLLED STUDY; GENE ACTIVATION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUICIDE GENE; T LYMPHOCYTE; ANIMAL; ANTIGEN PRESENTATION; DRUG SCREENING; GENE VECTOR; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; LEUKEMIA; LYMPHOCYTE ACTIVATION; LYMPHOMA; MOUSE MUTANT;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD19; ANTIGENS, CD28; CASPASE 9; GENETIC VECTORS; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-15; LEUKEMIA; LYMPHOCYTE ACTIVATION; LYMPHOMA; MICE; MICE, SCID; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77954590000     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.75     Document Type: Article

References (51)

1. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008; 112: 2261-2271.
2. Hombach A, Heuser C, Sircar R, Tillmann T, Diehl V, Pohl C et al. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen. J Immunother 1999; 22: 473-480. (Pubitemid 29526342)
3. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009; 21: 215-223.
4. Savoldo B, Rooney CM, Di Stasi A, Abken H, Hombach A, Foster AE et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30{zeta} artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood 2007; 110: 2620-2630. (Pubitemid 47523186)
5. Dotti G, Savoldo B, Brenner M. Fifteen years of gene therapy based on chimeric antigen receptors: 'are we nearly there yet?'. Hum Gene Ther 2009; 20: 1229-1239.
6. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993; 90: 720-724. (Pubitemid 23028937)
7. Cooper LJ, Topp MS, Serrano LM, Gonzalez S, Chang WC, Naranjo A et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 2003; 101: 1637-1644. (Pubitemid 36182545)
8. Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003; 9: 279-286. (Pubitemid 36362782)
9. Jensen M, Tan G, Forman S, Wu AM, Raubitschek A. CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy. Biol Blood Marrow Transplant 1998; 4: 75-83. (Pubitemid 128540943)
10. Vera J, Savoldo B, Vigouroux S, Biagi E, Pule M, Rossig C et al. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 2006; 108: 3890-3897. (Pubitemid 44864573)
11. Brentjens R, RIHDTCNYSJLJYRSESM. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I trial. Mole Ther 2010; 18: 666-668.
12. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006; 12 (20 Pt 1): 6106-6115. (Pubitemid 44703776)
13. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008; 14: 1264-1270.
14. Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006; 66: 10995-11004. (Pubitemid 44876999)
15. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 2002; 20: 70-75. (Pubitemid 34044918)
16. Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004; 18: 676-684. (Pubitemid 38500185)
17. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009; 17: 1453-1464.
18. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA 2009; 106: 3360-3365.
19. Tammana S, Huang X, Wong M, Milone MC, Ma L, Levine BL et al. 4-1BB and CD28 Signaling plays a synergistic role in redirecting umbilical cord blood t cells against B-cell malignancies. Hum Gene Ther 2010; 21: 75-86.
20. Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol 2009; 183: 5563-5574.
21. Wang J, Jensen M, Lin Y, Sui X, Chen E, Lindgren CG et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther 2007; 18: 712-725. (Pubitemid 47378068)
22. Pule MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 2005; 12: 933-941. (Pubitemid 41614489)
23. Ma A, Koka R, Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol 2006; 24: 657-679.
24. Waldmann TA, Dubois S, Tagaya Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 2001; 14: 105-110. (Pubitemid 32206513)
25. Hsu C, Jones SA, Cohen CJ, Zheng Z, Kerstann K, Zhou J et al. Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene. Blood 2007; 109: 5168-5177. (Pubitemid 46890533)
26. Straathof KC, Pule MA, Yotnda P, Dotti G, Vanin EF, Brenner MK et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005; 105: 4247-4254. (Pubitemid 40720769)
27. Quintarelli C, Vera JF, Savoldo B, Giordano Attianese GM, Pule M, Foster AE et al. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood 2007; 110: 2793-2802. (Pubitemid 350006931)
28. Rossig C, Brenner MK. Chimeric T-cell receptors for the targeting of cancer cells. Acta Haematol 2003; 110: 154-159. (Pubitemid 37340194)
29. Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009; 113: 6392-6402.
30. Kim YJ, Dubey P, Ray P, Gambhir SS, Witte ON. Multimodality imaging of lymphocytic migration using lentiviral-based transduction of a tri-fusion reporter gene. Mol Imaging Biol 2004; 6: 331-340. (Pubitemid 39243066)
31. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443: 350-354. (Pubitemid 44435155)
32. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3: 666-675. (Pubitemid 37328821)
33. Finney HM, Lawson AD, Bebbington CR, Weir AN. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol 1998; 161: 2791-2797. (Pubitemid 28425698)
34. Huang X, Guo H, Kang J, Choi S, Zhou TC, Tammana S et al. Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. Mol Ther 2008; 16: 580-589. (Pubitemid 351314999)
35. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009; 17: 1453-1464.
36. Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA 2004; 101: 1969-1974. (Pubitemid 38228999)
37. Roychowdhury S, May Jr KF, Tzou KS, Lin T, Bhatt D, Freud AG et al. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2. Cancer Res 2004; 64: 8062-8067. (Pubitemid 39446944)
38. Hsu C, Hughes MS, Zheng Z, Bray RB, Rosenberg SA, Morgan RA. Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine. J Immunol 2005; 175: 7226-7234. (Pubitemid 41713417)
39. Urbani S, Amadei B, Tola D, Massari M, Schivazappa S, Missale G et al. PD-1 expression in acute hepatitis C Virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol 2006; 80: 11398-11403. (Pubitemid 44706581)
40. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704. (Pubitemid 351600389)
41. Mumprecht S, Schurch C, Schwaller J, SolenthalerM, Ochsenbein AF. Programmed death 1 signaling on chronic myeloid leukemiaspecific T cells results in T-cell exhaustion and disease progression. Blood 2009; 114: 1528-1536.
42. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114: 1537-1544.
43. Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 2009; 114: 1545-1552.
44. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003; 9: 562-567. (Pubitemid 36597102)
45. Berger C, Berger M, Hackman RC, Gough M, Elliott C, Jensen MC et al. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 2009; 114: 2417-2426.
46. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8: 299-308. (Pubitemid 351430867)
47. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP et al. Adoptive cell transfer therapy following nonmyeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 2346-2357. (Pubitemid 46218728)
48. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263-274. (Pubitemid 40488632)
49. Ben AM, Belhadj HN, Moes N, Buyse S, Abdeladhim M, Louzir H et al. IL-15 renders conventional lymphocytes resistant to suppressive functions of regulatory T cells through activation of the phosphatidylinositol 3-kinase pathway. J Immunol 2009; 182: 6763-6770.
50. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006; 24: e20-e22.
51. Tey SK, Dotti G, Rooney CM, Heslop HE, Brenner MK. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 913-924. (Pubitemid 47055386)